The rest of the world, too, is wrestling with rising obesity. In the United States, 42% of adults are considered obese, and nearly three-quarters qualify as obese or overweight. The World Obesity Federation predicts that 51% of the global population will be overweight or obese by 2035.
Today, Novo sells semaglutide in three forms: as Ozempic, a once-weekly injectable for treating type 2 diabetes, and prescribed off-label for weight loss; Wegovy, a higher-dose injectable approved for weight loss; and Rybelsus, an oral type 2 diabetes drug.
[
add
]
[
|
|
...
]